Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods.

ABSTRACT: There is intense and widespread interest in developing monoclonal antibodies as therapeutic agents to treat diverse human disorders. During early-stage antibody discovery, hundreds to thousands of lead candidates are identified, and those that lack optimal physical and chemical properties must be deselected as early as possible to avoid problems later in drug development. It is particularly challenging to characterize such properties for large numbers of candidates with the low antibody quantities, concentrations, and purities that are available at the discovery stage, and to predict concentrated antibody properties (e.g., solubility, viscosity) required for efficient formulation, delivery, and efficacy. Here we review key recent advances in developing and implementing high-throughput meth

SUBMITTER: Makowski EK 

PROVIDER: S-EPMC8346245 | biostudies-literature | 2021 Jan-Dec

REPOSITORIES: biostudies-literature